###begin article-title 0
Analysis of inflammation- and atherosclerosis-related gene polymorphisms in branch retinal vein occlusion
###end article-title 0
###begin p 1
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Purpose
###end title 2
###begin p 3
Branch retinal vein occlusion (BRVO) is a common vision-threatening disease. Compression of the underlying retinal vein due to increased rigidity of the crossing artery has been implicated in the pathogenesis of BRVO. Among others, arterial hypertension and hypercholesterolemia, both of which contribute to atherogenesis, have been identified as risk factors. Atherosclerosis itself is a chronic low-grade inflammatory disease with a distinct pro-inflammatory cytokine pattern. In addition to their role in atherogenesis, some cytokines have been shown to exert procoagulatory effects, and may thus contribute to the development of BRVO by a second mechanism. Gene polymorphisms affecting the expression of inflammation-related cytokines are therefore candidates as potential risk factors for BRVO. The purpose of the present study was to investigate hypothesized associations between cytokine gene polymorphisms and the presence of BRVO.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 213 217 213 217 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL1B</italic>
###xml 263 268 263 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL1RN</italic>
###xml 294 297 294 297 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL4</italic>
###xml 323 326 323 326 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL6</italic>
###xml 352 355 352 355 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL8</italic>
###xml 382 386 382 386 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL10</italic>
###xml 413 417 413 417 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL18</italic>
###xml 450 453 450 453 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNF</italic>
###xml 500 504 500 504 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL2</italic>
###xml 528 532 528 532 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL5</italic>
###xml 24 32 <span type="species:ncbi:9606">patients</span>
The study comprised 398 patients with BRVO and 355 control subjects. Using 5'exonuclease assays (TaqMan), genotypes of the following functional single nucleotide polymorphisms were determined: interleukin 1 beta (IL1B) -511C>T, interleukin 1 receptor antagonist (IL1RN) 1018T>C, interleukin 4 (IL4) -584C>T, interleukin 6 (IL6) -174G>C, interleukin 8 (IL8) -251A>T, interleukin 10 (IL10) -592C>A, interleukin 18 (IL18) 183A>G, tumor necrosis factor (TNF) -308G>A, monocyte chemoattractant protein 1 (CCL2) -2518A>G, and RANTES (CCL5) -403G>A.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 131 139 <span type="species:ncbi:9606">patients</span>
###xml 238 246 <span type="species:ncbi:9606">patients</span>
Neither genotype distributions nor allele frequencies of any of the investigated polymorphisms differed significantly between BRVO patients and controls (p>0.05). Arterial hypertension was found to be significantly more prevalent in BRVO patients than in controls (p<0.001). In a logistic regression analysis presence of arterial hypertension was associated with an odds ratio of 3.33 (95% confidence interval: 2.42-4.57) for BRVO.
###end p 7
###begin title 8
Conclusions
###end title 8
###begin p 9
###xml 83 91 <span type="species:ncbi:9606">patients</span>
As none of the investigated gene variants was significantly more prevalent in BRVO patients than among control subjects, our data suggest that these polymorphisms themselves are unlikely major risk factors for BRVO.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 258 259 258 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r1">1</xref>
###xml 260 261 260 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r2">2</xref>
###xml 488 489 488 489 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r3">3</xref>
###xml 698 699 698 699 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r4">4</xref>
###xml 700 701 700 701 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r7">7</xref>
###xml 89 97 <span type="species:ncbi:9606">patients</span>
Branch retinal vein occlusion (BRVO) is a vision-threatening disease, commonly affecting patients older than 60 years. It frequently occurs at an arteriovenous crossing site, where the retinal vein shares a common adventitial sheath with the retinal artery [1,2]. Increased rigidity of the crossing artery resulting from atherosclerotic disease has been suggested to cause compression of the underlying vein, resulting in turbulent blood flow, endothelial damage, and thrombus formation [3]. Consequently, arterial hypertension, elevated plasma homocysteine concentrations, and hypercholesterolemia, all of which are known to contribute to atherogenesis, have been identified as BRVO risk factors [4-7].
###end p 11
###begin p 12
###xml 207 208 207 208 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</sub>
###xml 228 229 228 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
###xml 230 231 230 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r9">9</xref>
###xml 441 443 441 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r10">10</xref>
###xml 444 446 444 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r12">12</xref>
###xml 751 753 744 746 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r13">13</xref>
###xml 754 756 747 749 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r17">17</xref>
Atherosclerosis itself is a chronic low-grade inflammatory disease, which is characterized by the recruitment of both monocytes and T lymphocytes to the site of inflammation and a distinct pro-inflammatory TH1 cytokine pattern [8,9]. Animal experiments have provided some evidence that a lack of anti-inflammatory cytokines promotes atherogenesis, whereas deficiency of pro-inflammatory cytokines is associated with reduced atherosclerosis [10-12]. Importantly, cytokines and chemokines such as interleukin 1 beta (IL-1beta), interleukin 6 (IL-6), interleukin 8 (IL-8), tumor necrosis factor alpha (TNF-alpha), and monocyte chemoattractant protein 1 (MCP-1) have also been reported to affect hemostasis, and may thus contribute to thrombus formation [13-17].
###end p 12
###begin p 13
###xml 282 290 <span type="species:ncbi:9606">patients</span>
Single nucleotide polymorphisms (SNPs) affecting the expression of cytokines or chemokines previously implicated in atherogenesis as well as activation of the coagulation cascade are thus potential risk factors for BRVO. Nevertheless, they have not yet been investigated among BRVO patients. Consequently, in the present study, functional gene polymorphisms encoding the following cytokines or chemokines were chosen as candidate risk factors.
###end p 13
###begin p 14
###xml 374 376 368 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r18">18</xref>
###xml 377 379 371 373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r19">19</xref>
###xml 574 576 565 567 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r20">20</xref>
###xml 778 780 766 768 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r13">13</xref>
###xml 916 918 901 903 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r21">21</xref>
###xml 1003 1007 988 992 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL1B</italic>
###xml 1014 1018 999 1003 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL1B</italic>
###xml 1063 1067 1048 1052 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL1B</italic>
###xml 1095 1097 1080 1082 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r22">22</xref>
###xml 492 496 <span type="species:ncbi:10090">mice</span>
###xml 1266 1278 <span type="species:ncbi:9606">participants</span>
The pro-inflammatory cytokine IL-1beta exerts strong pro-atherogenic effects by enhancing expression of intercellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1) on endothelial cells. Furthermore, IL-1beta induces the synthesis of chemokines, such as IL-8 and MCP-1, and thus facilitates the transendothelial migration of inflammatory cells [18,19]. Additional evidence for its role in atherosclerosis comes from an animal model showing that in apoE-deficient mice a lack of IL-1beta is associated with decreased severity of atherosclerosis [20]. IL-1beta also exerts procoagulatory effects by increasing the expression of tissue factor, which itself plays an essential role in the activation of the extrinsic pathway of the coagulation cascade [13]. Furthermore, increased expression of IL-1beta downregulates tissue-type plasminogen activator (t-PA), and thus impairs fibrinolysis [21]. A gene polymorphism, characterized by a C to T transition at position -511 of the IL1B gene (IL1B-511C>T, rs16944), affects the expression of IL1B. Iacoviello and coworkers [22] found that stimulation with lipopolysaccharide (LPS) produced a significant decrease in tissue factor expression as well as IL-1beta release in mononuclear cells from participants carrying the -511TT genotype compared to those homozygous for the -511C allele.
###end p 14
###begin p 15
###xml 157 159 154 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r18">18</xref>
###xml 272 274 269 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r23">23</xref>
###xml 275 277 272 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r24">24</xref>
###xml 338 343 335 340 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL1RN</italic>
###xml 493 495 490 492 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r25">25</xref>
By binding to the IL-1 receptor without transmitting the agonist signal, the interleukin 1 receptor antagonist (IL-1Ra) counter-regulates IL-1beta activity [18]. Animal models have demonstrated that deficiency of IL-1Ra affects the development of atherosclerotic lesions [23,24]. Recently, a polymorphism within the gene encoding IL-1Ra (IL1RN 1018T>C, rs4251961) has been associated with both decreased IL-1Ra production and increased IL-6 and C-reactive protein (CRP) plasma concentrations [25].
###end p 15
###begin p 16
###xml 336 338 336 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r26">26</xref>
###xml 339 341 339 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r29">29</xref>
###xml 485 487 485 487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r30">30</xref>
###xml 488 490 488 490 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r31">31</xref>
###xml 562 564 562 564 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r32">32</xref>
###xml 677 680 677 680 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL4</italic>
###xml 687 690 687 690 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL4</italic>
###xml 784 786 784 786 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r33">33</xref>
###xml 357 361 <span type="species:ncbi:10090">mice</span>
###xml 774 782 <span type="species:ncbi:9606">patients</span>
Several studies support an important pathogenic role of interleukin 4 (IL-4) in atherogenesis. IL-4 mediates proatherogenic pathways by both increasing the expression of MCP-1, IL-6, VCAM-1, and by upregulation of 15-lipoxygenase, which itself plays an essential role in oxidizing low-density lipoprotein (LDL) to its atherogenic form [26-29]. Furthermore, mice experiments have provided evidence that IL-4 deficiency is associated with decreased formation of atherosclerotic lesions [30,31]. IL-4 promotes fibrinolysis by stimulating monocytes to produce t-PA [32]. A functional IL-4 polymorphism, which is characterized by a C to T substitution in the promoter region of the IL4 gene (IL4 -584C>T, rs2243250), has been identified; thus far, it not been studied among BRVO patients [33].
###end p 16
###begin p 17
###xml 116 118 116 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r34">34</xref>
###xml 267 269 267 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r35">35</xref>
###xml 448 450 448 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r10">10</xref>
###xml 573 575 573 575 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r36">36</xref>
###xml 576 578 576 578 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r38">38</xref>
###xml 679 681 679 681 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r39">39</xref>
###xml 787 790 787 790 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL6</italic>
###xml 863 866 863 866 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL6</italic>
###xml 1170 1172 1170 1172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r40">40</xref>
###xml 1326 1328 1326 1328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r41">41</xref>
###xml 1350 1353 1350 1353 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL6</italic>
###xml 1514 1516 1514 1516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r42">42</xref>
IL-6 is a pleiotropic, pro-inflammatory cytokine, which is synthesized by monocytes and vascular endothelial cells [34]. It has been shown to contribute to atherogenesis by induction of endothelial dysfunction and enhancement of the expression of adhesion molecules [35]. In animal experiments, IL-6 has been observed to promote the development of early atherosclerotic lesions, thus strongly confirming an essential role of IL-6 in atherogenesis [10]. Furthermore, IL-6 promotes coagulation by upregulating the transcription of tissue factor, fibrinogen, and factor VIII [36-38]. Interestingly, IL-6 plasma levels have been reported as a risk determinant for venous thrombosis [39]. In 1998, Fishman and coworkers identified a functional gene polymorphism in the promoter region of the IL6 gene, which is characterized by a C to T substitution at position -174 (IL6-174G>C, ). Using transfected HeLa cells, Fishman and colleagues found higher baseline IL-6 levels in cells with the G construct compared to those transfected with the C allele. Stimulation with LPS or IL-1 resulted in a significantly increased IL-6 transcription rate among cells carrying the G allele [40]. Another study using anti CD3/CD28-stimulated peripheral blood lymphocytes found three times higher IL-6 concentrations among carriers of the G allele [41]. Interestingly, the IL6-174G>C polymorphism has previously been suggested to affect susceptibility to retinal artery occlusion (RAO). Its role in BRVO, however, still remains elusive [42].
###end p 17
###begin p 18
###xml 69 70 69 70 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</sub>
###xml 292 294 281 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r43">43</xref>
###xml 381 383 370 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r12">12</xref>
###xml 488 490 477 479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r44">44</xref>
###xml 589 591 578 580 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r45">45</xref>
###xml 786 790 775 779 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL10</italic>
###xml 797 799 786 788 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r46">46</xref>
###xml 800 802 789 791 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r47">47</xref>
###xml 917 921 906 910 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL10</italic>
###xml 950 954 939 943 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL10</italic>
###xml 1148 1152 1137 1141 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL10</italic>
###xml 1205 1207 1194 1196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r48">48</xref>
In contrast to IL-6, interleukin 10 (IL-10) is an anti-inflammatory TH2-associated cytokine that mediates anti-atherogenic pathways by suppressing the synthesis of several pro-inflammatory cytokines such as IL-1beta, IL-6, interleukin 12 (IL-12), TFN-alpha, and interferon-gamma (IFN-gamma) [43]. Its protective role in atherogenesis has also been confirmed by animal experiments [12]. As for hemostasis, IL-10 has been shown to inhibit LPS induced tissue factor expression in monocytes [44]. Gene polymorphisms are thought to account for up to 75% of the variability of IL-10 production [45], and increased IL-10 expression has been associated with the presence of a TCATA haplotype formed by polymorphisms at position -3575, -2763, -1082, -819, and -592 in the promoter region of the IL10 gene [46,47]. Due to strong linkage disequilibrium, the presence of this haplotype can be fully determined by analysis of the IL10-592C>A polymorphism (). The IL10-592A allele indicates the presence of the presumed anti-inflammatory TCATA haplotype, while the -592C allele indicates its absence. As for retinal vascular diseases, an association between the IL10-592C>A polymorphism and RAO risk has been reported [48].
###end p 18
###begin p 19
###xml 194 195 194 195 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</sub>
###xml 250 252 246 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r19">19</xref>
###xml 394 396 387 389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r49">49</xref>
###xml 587 589 580 582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r50">50</xref>
###xml 590 592 583 585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r51">51</xref>
###xml 799 803 792 796 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL18</italic>
###xml 810 812 803 805 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r52">52</xref>
###xml 834 838 827 831 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL18</italic>
###xml 976 980 969 973 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL18</italic>
###xml 416 420 <span type="species:ncbi:10090">mice</span>
Animal models have also provided evidence that the pro-inflammatory cytokine interleukin 18 (IL-18) contributes to the development of atherosclerosis. In synergy with IL-12, IL-18 promotes the TH1 immune response by inducing the IFN-gamma synthesis [19]. It also upregulates the synthesis of pro-inflammatory cytokines such as IL-1beta and IL-8 as well as the expression of adhesion molecules [49]. In apoE knockout mice, administration of IL-18 has been associated with enhancement of atherosclerosis, whereas deficiency of IL-18 has been shown to reduce the extent of atherosclerosis [50,51]. IL-18 expression has been found to be decreased among carriers of the GCAGT haplotype formed by polymorphisms at position -887, -105, +105, +183, and +533 in the promoter and 5'untranslated region of the IL18 gene [52]. By analysis of the IL18+183A>G polymorphism () the GCAGT haplotype can be identified, since this haplotype is the only one including the +183G allele. Thus, the IL18+183G allele indicates the presence of this haplotype, while the +183A allele indicates its absence.
###end p 19
###begin p 20
###xml 173 175 169 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r19">19</xref>
###xml 367 369 359 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r53">53</xref>
###xml 493 495 481 483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r54">54</xref>
###xml 659 661 643 645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r14">14</xref>
###xml 662 664 646 648 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r15">15</xref>
###xml 759 761 739 741 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r55">55</xref>
###xml 390 394 <span type="species:ncbi:10090">mice</span>
Overexpression of TNF-alpha, a potent pro-inflammatory cytokine mainly produced by macrophages and T cells, has also been implicated in the pathogenesis of atherosclerosis [19]. TNF-alpha upregulates both the expression of adhesion molecules (ICAM-1, VCAM-1) and chemokines such as MCP-1, thereby facilitating the recruitment of monocytes to atherosclerotic lesions [53]. In apoE-deficient mice a lack of TNF-alpha was observed to be associated with a reduced size of atherosclerotic lesions [54]. TNF-alpha also exerts procoagulatory effects by upregulating tissue factor expression and by inhibition of the thrombomodulin/protein C anticoagulation pathway [14,15]. In addition, impairment of fibrinolysis is caused by TNF-alpha induced t-PA downregulation [55].
###end p 20
###begin p 21
###xml 2 5 2 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNF</italic>
###xml 94 97 94 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNF</italic>
###xml 104 107 104 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNF</italic>
###xml 198 201 194 197 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNF</italic>
###xml 357 359 349 351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r56">56</xref>
A TNF promoter polymorphism, which is caused by a G to A substitution at position -308 of the TNF gene (TNF-308G>A, ), has been reported to modulate the expression of TNF-alpha. The presence of the TNF-308A allele has been found to be associated with higher constitutive and inducible TNF-alpha levels after LPS stimulation compared to the -308GG genotype [56].
###end p 21
###begin p 22
###xml 404 406 396 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r57">57</xref>
###xml 564 566 556 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r58">58</xref>
###xml 567 569 559 561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r59">59</xref>
###xml 671 673 663 665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r60">60</xref>
###xml 736 740 728 732 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL2</italic>
###xml 795 797 787 789 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r61">61</xref>
###xml 1015 1017 1004 1006 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r61">61</xref>
Importantly, the migration of leukocytes to the site of inflammation occurs along a gradient of various chemokines including MCP-1, IL-8, and RANTES (regulated on activation, normal T cell expressed and secreted). MCP-1 belongs to the CC family of chemokines, and its expression in both endothelial cells and monocytes can be induced by pro-inflammatory cytokines such as IL-1, IFN-gamma, and TNF-alpha [57]. A large body of evidence indicates that MCP-1 plays an essential role in atherogenesis by recruiting monocytes and macrophages to atherosclerotic lesions [58,59]. MCP-1 has also been reported to have a procoagulant function by inducing tissue factor expression [60]. An A to G substitution at position -2518 of the MCP-1 gene (CCL2-2518A>G, ) has been noted to affect MCP-1 expression [61]. After IL-1beta stimulation, peripheral blood mononuclear cells from individuals carrying the -2518G allele showed a significantly higher MCP-1 synthesis than cells from individuals homozygous for the -2518A allele [61].
###end p 22
###begin p 23
###xml 138 140 134 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r62">62</xref>
###xml 353 355 349 351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r63">63</xref>
###xml 459 461 455 457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r64">64</xref>
###xml 547 549 543 545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r13">13</xref>
###xml 572 574 568 570 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r65">65</xref>
###xml 630 633 626 629 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL8</italic>
###xml 700 703 696 699 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL8</italic>
###xml 719 722 715 718 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL8</italic>
###xml 905 907 901 903 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r66">66</xref>
###xml 427 431 <span type="species:ncbi:10090">mice</span>
Endothelial secretion of IL-8, a member of the CXC chemokine family, is induced by pro-inflammatory cytokines such as IL-1 and TNF-alpha [62]. IL-8 is a potent chemoattractant for neutrophils, and, like MCP-1, also triggers firm adhesion of rolling monocytes to the vascular endothelium, thus contributing to the development of atherosclerotic lesions [63]. Decreased susceptibility to atherosclerosis has been demonstrated in mice lacking the IL-8 receptor [64]. IL-8 has also been shown to increase the expression of tissue factor in monocytes [13]. Hull and coworkers [65] identified a common SNP in the promoter region of the IL8 gene, which is caused by an A to T substitution at position -251 (IL8-251A>T, ). The IL8-251T allele was found to be associated with a two- to fivefold stronger luciferase expression than the -251A allele, suggesting a pro-inflammatory effect in carriers of this allele [66].
###end p 23
###begin p 24
###xml 210 212 210 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r67">67</xref>
###xml 296 298 296 298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r68">68</xref>
###xml 447 449 447 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r69">69</xref>
###xml 501 505 501 505 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL5</italic>
###xml 567 571 567 571 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL5</italic>
###xml 603 605 603 605 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r70">70</xref>
###xml 327 332 <span type="species:ncbi:10090">mouse</span>
Finally, RANTES, a member of the CC family of chemokines, is produced by T lymphocytes and monocytes. As a potent chemoattractant, RANTES has been shown to trigger monocyte arrest on dysfunctional endothelium [67]. Furthermore, RANTES is expressed by T cells in advanced atherosclerotic lesions [68]. In a hypercholesterolemic mouse model, administration of the CC chemokine antagonist Met-RANTES resulted in reduced atherosclerotic lesion sizes [69]. A SNP in the promoter region of the RANTES gene (CCL5), which is caused by a G to A substitution at position -403 (CCL5-403G>A, ) has been identified [70]. In cells transfected with the -403A variant, increased transcriptional activity has been demonstrated.
###end p 24
###begin p 25
So far none of these functional gene polymorphisms has been studied as a potential risk factor for BRVO. The purpose of the present study was thus to investigate a hypothesized association between the aforementioned gene polymorphisms and the presence of BRVO.
###end p 25
###begin title 26
Methods
###end title 26
###begin p 27
###xml 31 39 <span type="species:ncbi:9606">patients</span>
###xml 148 156 <span type="species:ncbi:9606">patients</span>
###xml 269 281 <span type="species:ncbi:9606">participants</span>
###xml 648 660 <span type="species:ncbi:9606">participants</span>
The present study enrolled 398 patients with BRVO (228 females and 170 males) and 355 control subjects (206 females and 149 males). The mean age of patients was 67.1+/-11.0 years (range: 37-93 years) and 68.3+/-13.8 years (range: 21-93 years) in the control group. All participants were of Caucasian origin, living in the same geographical area and were seen at the local Department of Ophthalmology, Medical University of Graz. The study was approved by the Institutional Review Board of the Medical University of Graz and followed the principles of the Declaration of Helsinki. Prior to enrollment, written informed consent was obtained from all participants. Diagnosis of BRVO was made if fundus examination revealed venous dilation and tortuosity with intraretinal hemorrhages in a wedge-shaped region, with the apex of the wedge pointing to an arteriovenous crossing point.
###end p 27
###begin p 28
###xml 51 59 <span type="species:ncbi:9606">patients</span>
###xml 297 305 <span type="species:ncbi:9606">patients</span>
The control group was hospital-based and comprised patients seen at the Department of Ophthalmology, Medical University of Graz for reasons other than retinal vascular occlusion, such as cataract or glaucoma surgery. All controls underwent a detailed fundus examination. Excluded as controls were patients who had a history of retinal vascular occlusions, deep vein thrombosis, pulmonary embolism, myocardial infarction, or stroke.
###end p 28
###begin p 29
###xml 159 171 <span type="species:ncbi:9606">Participants</span>
###xml 409 421 <span type="species:ncbi:9606">Participants</span>
Arterial hypertension was defined by a systolic blood pressure >/=140 mmHg, a diastolic blood pressure of >/=90 mmHg, or the intake of antihypertensive drugs. Participants were classified as diabetics if they were being treated for insulin or non-insulin-dependent diabetes mellitus. Hypercholesterolemia was defined by fasting plasma cholesterol levels above 200 mg/dl or the intake of lipid-lowering drugs. Participants were classified as either ever (current/previous) smokers or nonsmokers. A standardized questionnaire was employed to obtain data on medication intake as well as history of deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke.
###end p 29
###begin p 30
###xml 777 784 771 778 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1">Table 1</xref>
Candidate gene polymorphisms were selected using the following criteria: association of the polymorphism with gene expression or activity of the gene product; involvement of the gene product in pro- or anti-inflammatory pathways; a minor allele frequency of 5% or higher; and no data available on the role of this gene variant in BRVO. Genomic DNA was isolated from whole blood by standard methods (QIA-AMP DNA, blood mini kit, Qiagen, Vienna, Austria) and stored at -20 degreesC. Genotypes of the aforedescribed polymorphisms were determined by 5' exonuclease assays (TaqMan). Applied Biosystems Assay-by-Design custom service (Applied Biosystems, Vienna, Austria) was used for design and manufacture of primer and probe sets. Sequences of primers and probes are presented in Table 1. Endpoint fluorescence data were exported into Excel format and analyzed as scatter plots. Samples were analyzed in batches, each containing 94 samples and 2 negative controls (water instead of DNA). Next, 50 samples were reanalyzed, and the results were identical for all samples.
###end p 30
###begin title 31
Sequences of primers and probes for TaqMan genotyping assays.
###end title 31
###begin p 32
Sequences of primers and probes for TaqMan genotyping assays are presented. FAM and VIC are names of fluorescent dyes. NFQ is the abbreviation for non-fluorescent quencher.
###end p 32
###begin title 33
Statistics
###end title 33
###begin p 34
###xml 142 143 142 143 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 257 258 253 254 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
SPSS for windows (release 15.0.1; SPSS, Inc., Chicago, IL) was used for statistical analyses. Continuous variables were analyzed by Student's t-test and presented as means+/-SD. Categorial variables were presented as percentages and were compared by the chi2 test. Odds ratios and 95% confidence intervals (CI) were calculated by logistic regression analysis, and genotypes were coded assuming an allele dose effect (wildtype genotype=0, heterozygous carrier of the mutated allele=1, homozygous carrier for the mutated allele=2). A p<0.05 was considered statistically significant.
###end p 34
###begin title 35
Results
###end title 35
###begin p 36
###xml 53 60 53 60 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t2">Table 2</xref>
###xml 361 368 361 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t2">Table 2</xref>
###xml 125 133 <span type="species:ncbi:9606">patients</span>
###xml 261 269 <span type="species:ncbi:9606">patients</span>
Clinical characteristics of both groups are shown in Table 2. Arterial hypertension was significantly more prevalent in BRVO patients than among control subjects (76.9% versus 51.5%; p<0.001). Hypercholesterolemia and ever-smoking status were also higher among patients than in the control group; however neither characteristics were statistically significant (Table 2).
###end p 36
###begin title 37
###xml 20 28 <span type="species:ncbi:9606">patients</span>
Demographic data of patients with branch retinal vein occlusion and control subjects.
###end title 37
###begin p 38
###xml 101 109 <span type="species:ncbi:9606">patients</span>
Prevalence of arterial hypertension was significantly higher in branch retinal vein occlusion (BRVO) patients compared to control subjects. Data are mean+/-standard deviation, or number of subjects (%).
###end p 38
###begin p 39
###xml 0 7 0 7 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t3">Table 3</xref>
###xml 482 484 482 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r22">22</xref>
###xml 485 487 485 487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r25">25</xref>
###xml 488 490 488 490 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r52">52</xref>
###xml 491 493 491 493 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r71">71</xref>
###xml 494 496 494 496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r77">77</xref>
###xml 650 657 650 657 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t4">Table 4</xref>
###xml 71 79 <span type="species:ncbi:9606">patients</span>
###xml 243 251 <span type="species:ncbi:9606">patients</span>
Table 3 presents genotype distributions and allele frequencies in BRVO patients and controls. Neither allele frequencies nor genotype distributions of any of the investigated gene polymorphisms were found to be significantly different between patients and controls. Observed genotype distributions were in line with those predicted by the Hardy-Weinberg equilibrium, and allele frequencies among controls were similar to those previously observed among other Caucasian populations [22,25,52,71-77]. In a logistic regression analysis, presence of BRVO was predicted by arterial hypertension, but not by any of the ten investigated gene polymorphisms (Table 4).
###end p 39
###begin title 40
###xml 35 43 <span type="species:ncbi:9606">patients</span>
Genotype and allele frequencies in patients with branch retinal vein occlusion and control subjects.
###end title 40
###begin p 41
###xml 110 118 <span type="species:ncbi:9606">patients</span>
Genotype and allele frequencies were not significantly different between branch retinal vein occlusion (BRVO) patients and control subjects, suggesting that these genotypes are not associated with BRVO risk.
###end p 41
###begin title 42
Logistic regression analysis of branch retinal vein occlusion risk.
###end title 42
###begin p 43
Arterial hypertension, but none of the investigated gene polymorphisms, was significantly associated with branch retinal vein occlusion (BRVO) risk.
###end p 43
###begin title 44
Discussion
###end title 44
###begin p 45
###xml 179 180 179 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r3">3</xref>
###xml 1002 1004 1002 1004 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r77">77</xref>
###xml 1005 1007 1005 1007 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r83">83</xref>
Increased rigidity of the retinal artery leading to compression of the underlying vein at an arteriovenous crossing site has strongly been implicated in the pathogenesis of BRVO [3]. We hypothesized that BRVO susceptibility might be conferred by functional gene polymorphisms that affected the expression of cytokines or chemokines, which themselves have all been shown to affect atherogenesis. In addition, some cytokines also exert procoagulatory effects and may thus affect BRVO risk by a second mechanism. To improve biologic plausibility gene polymorphisms were only selected as candidate risk factors when these polymorphisms had previously been associated with gene expression or activity of the gene product, and an essential role of the gene product in pro- or anti-inflammatory pathways had been known. Some of these polymorphisms have been associated with cardiovascular diseases, indicating that alterations in the genetics of the inflammatory system may modify the risk of these diseases [77-83].
###end p 45
###begin p 46
###xml 366 376 366 376 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL4&#8722;584C&gt;T</italic>
###xml 678 688 674 684 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL4&#8722;584C&gt;T</italic>
###xml 129 137 <span type="species:ncbi:9606">patients</span>
Neither genotype distributions nor allele frequencies of the investigated gene polymorphisms differed significantly between BRVO patients and control subjects. The statistical power of the present study to detect a potential association between the investigated gene polymorphisms and BRVO was calculated for the polymorphism with the lowest minor allele frequency (IL4-584C>T). For this polymorphism, the present study had a statistical power of 0.80 to detect an odds ratio of >/=1.55, and a statistical power of 0.99 to detect an odds ratio of >/=2.0 for carriers of the mutated allele. For all other polymorphisms, the statistical power was equal or higher than that of the IL4-584C>T polymorphism. Thus, our results strongly suggest that none of these gene variants is likely a major risk factor for BRVO.
###end p 46
###begin p 47
###xml 102 104 102 104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r26">26</xref>
###xml 105 107 105 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r49">49</xref>
###xml 108 110 108 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r57">57</xref>
###xml 111 113 111 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r62">62</xref>
###xml 226 228 222 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r57">57</xref>
The expression of cytokines and chemokines is also affected by factors other than gene polymorphisms [26,49,57,62]. For example, the expression of MCP-1 can be induced by pro-inflammatory cytokines such as IL-1 and TFN-alpha [57]. Thus, our finding that the investigated gene polymorphisms were not associated with a significantly increased risk for BRVO does not necessarily argue against a role of these cytokines and chemokines in the pathogenesis of BRVO.
###end p 47
###begin p 48
Large prospective studies are clearly warranted to elucidate whether altered plasma concentrations of both cytokines and chemokines are predictive for the development of BRVO. This, however, can only be achieved by conducting a prospective instead of a retrospective study. Yet, it is also possible that increased expression of inflammatory mediators may not be detected systemically in blood, but only locally in the vascular wall.
###end p 48
###begin p 49
###xml 1283 1285 1283 1285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r84">84</xref>
###xml 403 409 <span type="species:ncbi:9606">person</span>
When interpreting the data of the present study, some limitations have to be considered. First, blood samples were obtained after the occurrence of BRVO. Thus, the present study is not suitable to investigate plasma cytokine and chemokine patterns. The aim of this study, however, was to investigate a hypothesized association between genetic variants and BRVO risk. As genotypes do not change during a person's lifetime, the aforementioned limitation does not apply to the analysis of gene polymorphisms. Second, gene variants have been shown to vary between populations of different ethnic origins. Thus, our findings may not necessarily apply to ethnicities other than Caucasian. Finally, genetic studies are designed to compare allele or genotype frequencies between case and control groups. A statistical difference in frequencies between cases and controls suggests that the investigated genetic variant is associated with the disease. In the present candidate gene approach, we selected genetic polymorphisms on the basis of prior knowledge of gene function and allele frequencies. Thus, the candidate gene approach has the advantage of a higher probability of true association, which has been recognized as an important factor influencing the outcome of association studies [84]. The main limitation of the candidate gene approach is the usually low number of polymorphisms investigated. Whole genome association studies, including hundreds of thousands of polymorphisms, are now available. It is likely that results of such studies will provide novel candidates for genetic susceptibility to BRVO.
###end p 49
###begin p 50
###xml 98 106 <span type="species:ncbi:9606">patients</span>
In conclusion, as none of the investigated gene variants was significantly more prevalent in BRVO patients than among control subjects, our data suggest that these polymorphisms are unlikely major risk factors for BRVO in a Caucasian population.
###end p 50
###begin title 51
Acknowledgments
###end title 51
###begin p 52
This study was supported by the Anniversary Fund of the Oesterreichische Nationalbank (Project-Nr. 12245). We thank Ms. Gabriele Trummer, Ms. Christa Wachswender, and Ms. Manuela Fischl for their excellent technical assistance.
###end p 52
###begin title 53
References
###end title 53
###begin article-title 54
Histopathologic study of nine branch retinal vein occlusions.
###end article-title 54
###begin article-title 55
Arteriovenous crossing patterns in branch retinal vein occlusion. The Eye Disease Case-Control Study Group.
###end article-title 55
###begin article-title 56
Risk factors for branch retinal vein occlusion.
###end article-title 56
###begin article-title 57
Retinal vein occlusion and traditional risk factors for atherosclerosis.
###end article-title 57
###begin article-title 58
Retinal vein occlusion: a form of venous thrombosis or a complication of atherosclerosis? A meta-analysis of thrombophilic factors.
###end article-title 58
###begin article-title 59
Meta-analysis of plasma homocysteine, serum folate, serum vitamin B(12), and thermolabile MTHFR genotype as risk factors for retinal vascular occlusive disease.
###end article-title 59
###begin article-title 60
Atherosclerosis - an inflammatory disease.
###end article-title 60
###begin article-title 61
###xml 32 37 <span type="species:ncbi:9606">human</span>
Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines.
###end article-title 61
###begin article-title 62
###xml 51 55 <span type="species:ncbi:10090">mice</span>
Interleukin-6 exacerbates early atherosclerosis in mice.
###end article-title 62
###begin article-title 63
###xml 75 79 <span type="species:ncbi:10090">mice</span>
Exogenous interferon-gamma enhances atherosclerosis in apolipoprotein E-/- mice.
###end article-title 63
###begin article-title 64
###xml 112 116 <span type="species:ncbi:10090">mice</span>
Overexpression of interleukin-10 by activated T lymphocytes inhibits atherosclerosis in LDL receptor- deficient mice by altering lymphocyte and macrophage phenotypes.
###end article-title 64
###begin article-title 65
Cytokines and hemostasis.
###end article-title 65
###begin article-title 66
Activation of coagulation after administration of tumor necrosis factor to normal subjects.
###end article-title 66
###begin article-title 67
Tumor necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells.
###end article-title 67
###begin article-title 68
The relationship between inflammation and venous thrombosis. A systematic review of clinical studies.
###end article-title 68
###begin article-title 69
###xml 59 65 <span type="species:ncbi:9606">humans</span>
Interleukin-6 stimulates coagulation, not fibrinolysis, in humans.
###end article-title 69
###begin article-title 70
Biologic basis for interleukin-1 in disease.
###end article-title 70
###begin article-title 71
Cytokines in the pathogenesis of atherosclerosis.
###end article-title 71
###begin article-title 72
###xml 87 91 <span type="species:ncbi:10090">mice</span>
Lack of interleukin-1 beta decreases the severity of atherosclerosis in ApoE-deficient mice.
###end article-title 72
###begin article-title 73
IL-1beta down-regulates tissue-type plasminogen activator by up-regulating low-density lipoprotein receptor-related protein in AML 12 cells.
###end article-title 73
###begin article-title 74
IGIGI Investigators. Polymorphisms of the interleukin-1beta gene affect the risk of myocardial infarction and ischemic stroke at young age and the response of mononuclear cells to stimulation in vitro.
###end article-title 74
###begin article-title 75
###xml 51 55 <span type="species:ncbi:10090">mice</span>
Genetic alterations of IL-1 receptor antagonist in mice affect plasma cholesterol level and foam cell lesion size.
###end article-title 75
###begin article-title 76
###xml 101 105 <span type="species:ncbi:10090">mice</span>
Lack of interleukin-1 receptor antagonist modulates plaque composition in apolipoprotein E-deficient mice.
###end article-title 76
###begin article-title 77
Polymorphisms of the IL-1 receptor antagonist gene (IL1RN) are associated with multiple markers of systemic inflammation.
###end article-title 77
###begin article-title 78
Regulation of vascular cell adhesion molecule-1 expression by IL-4 and TNF-alpha in cultured endothelial cells.
###end article-title 78
###begin article-title 79
TNF-alpha and IL-4 synergistically increase vascular cell adhesion molecule-1 expression in cultured vascular smooth muscle cells.
###end article-title 79
###begin article-title 80
###xml 59 64 <span type="species:ncbi:9606">human</span>
Specific inflammatory cytokines regulate the expression of human monocyte 15-lipoxygenase.
###end article-title 80
###begin article-title 81
Pro-atherogenic effect of interleukin-4 in endothelial cells: modulation of oxidative stress, nitric oxide and monocyte chemoattractant protein-1 expression.
###end article-title 81
###begin article-title 82
###xml 113 117 <span type="species:ncbi:10090">mice</span>
The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice.
###end article-title 82
###begin article-title 83
###xml 121 125 <span type="species:ncbi:10090">mice</span>
Interleukin-4 deficiency decreases atherosclerotic lesion formation in a site-specific manner in female LDL receptor -/- mice.
###end article-title 83
###begin article-title 84
###xml 25 30 <span type="species:ncbi:9606">human</span>
Interleukin-4 stimulates human monocytes to produce tissue-type plasminogen activator.
###end article-title 84
###begin article-title 85
Promoter polymorphisms predisposing to the development of asthma and atopy.
###end article-title 85
###begin article-title 86
Interleukin-6: an overview.
###end article-title 86
###begin article-title 87
Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment.
###end article-title 87
###begin article-title 88
###xml 10 15 <span type="species:ncbi:9606">human</span>
Effect of human recombinant interleukin-6 and interleukin-8 on monocyte procoagulant activity.
###end article-title 88
###begin article-title 89
Regulation of fibrinogen biosynthesis: glucocorticoid and interleukin-6 control.
###end article-title 89
###begin article-title 90
Transcriptional activation of the factor VIII gene in liver cell lines by interleukin-6.
###end article-title 90
###begin article-title 91
###xml 33 41 <span type="species:ncbi:9606">patients</span>
Activation of innate immunity in patients with venous thrombosis: the Leiden Thrombophilia Study.
###end article-title 91
###begin article-title 92
The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis.
###end article-title 92
###begin article-title 93
Association of cytokine polymorphic inheritance and in vitro cytokine production in anti-CD3/CD28 stimulated peripheral blood lymphocytes.
###end article-title 93
###begin article-title 94
Role of the interleukin-6 -174G>C gene polymorphism in retinal artery occlusion.
###end article-title 94
###begin article-title 95
IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells.
###end article-title 95
###begin article-title 96
###xml 75 80 <span type="species:ncbi:9606">human</span>
Interleukin-10 inhibits endotoxin-induced tissue factor mRNA production by human monocytes.
###end article-title 96
###begin article-title 97
Heritability estimates of innate immunity: an extended twin study.
###end article-title 97
###begin article-title 98
Novel single nucleotide polymorphisms in the distal IL-10 promoter affect IL-10 production and enhance the risk of systemic lupus erythematosus.
###end article-title 98
###begin article-title 99
Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation.
###end article-title 99
###begin article-title 100
Haplotype-tagging interleukin-10 promoter polymorphism is associated with reduced risk of retinal artery occlusion.
###end article-title 100
###begin article-title 101
###xml 107 112 <span type="species:ncbi:9606">human</span>
Interleukin-18 (IFNgamma-inducing factor) induces IL-8 and IL-1beta via TNFalpha production from non-CD14+ human blood mononuclear cells.
###end article-title 101
###begin article-title 102
###xml 78 82 <span type="species:ncbi:10090">mice</span>
Reduced atherosclerosis in interleukin-18 deficient apolipoprotein E-knockout mice.
###end article-title 102
###begin article-title 103
###xml 65 69 <span type="species:ncbi:10090">mice</span>
Interleukin-18 enhances atherosclerosis in apolipoprotein E(-/-) mice through release of interferon-gamma.
###end article-title 103
###begin article-title 104
AtheroGene Investigators. Genetic analysis of interleukin-18 system highlights the role of interleukin-18 gene in cardiovascular disease.
###end article-title 104
###begin article-title 105
The pathophysiology of tumor necrosis factors.
###end article-title 105
###begin article-title 106
###xml 111 115 <span type="species:ncbi:10090">mice</span>
Disruption of tumor necrosis factor-alpha gene diminishes the development of atherosclerosis in ApoE-deficient mice.
###end article-title 106
###begin article-title 107
TNF-alpha mediated suppression of tissue type plasminogen activator expression in vascular endothelial cells is NF-kappaB- and p38 MAPK-dependent.
###end article-title 107
###begin article-title 108
###xml 153 159 <span type="species:ncbi:9606">humans</span>
Tumor necrosis factor (TNF) gene polymorphism influences TNF-alpha production in lipopolysaccharide (LPS)-stimulated whole blood cell culture in healthy humans.
###end article-title 108
###begin article-title 109
Monocyte chemotactic and activating factor gene expression induced in endothelial cells by IL-1 and tumor necrosis factor.
###end article-title 109
###begin article-title 110
###xml 39 43 <span type="species:ncbi:10090">mice</span>
Decreased lesion formation in CCR2 -/- mice reveals a role for chemokines in the initiation of atherosclerosis.
###end article-title 110
###begin article-title 111
###xml 94 98 <span type="species:ncbi:10090">mice</span>
Monocyte chemoattractant protein-1 accelerates atherosclerosis in apoliopoprotein E-deficient mice.
###end article-title 111
###begin article-title 112
###xml 66 71 <span type="species:ncbi:9606">human</span>
Tissue factor is induced by monocyte chemoattractant protein-1 in human aortic smooth muscle and THP-1 cells.
###end article-title 112
###begin article-title 113
A novel polymorphism in the MCP-1 gene regulatory region that influences MCP-1 expression.
###end article-title 113
###begin article-title 114
Interleukin-1 induces interleukin-8 secretion from endothelial cells by a juxtacrine mechanism.
###end article-title 114
###begin article-title 115
MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions.
###end article-title 115
###begin article-title 116
###xml 144 148 <span type="species:ncbi:10090">mice</span>
A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor-deficient mice.
###end article-title 116
###begin article-title 117
###xml 15 42 <span type="species:ncbi:12814">respiratory syncytial virus</span>
Association of respiratory syncytial virus bronchiolitis with the interleukin 8 gene region in UK families.
###end article-title 117
###begin article-title 118
The -251T allele of the interleukin-8 promoter is associated with increased risk of gastric carcinoma featuring diffuse-type histopathology in Chinese population.
###end article-title 118
###begin article-title 119
RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium.
###end article-title 119
###begin article-title 120
###xml 46 51 <span type="species:ncbi:9606">human</span>
Local expression of inflammatory cytokines in human atherosclerotic plaques.
###end article-title 120
###begin article-title 121
###xml 75 79 <span type="species:ncbi:10090">mice</span>
Antagonism of RANTES receptors reduces atherosclerotic plaque formation in mice.
###end article-title 121
###begin article-title 122
Atopic dermatitis is associated with a functional mutation in the promoter of the C-C chemokine RANTES.
###end article-title 122
###begin article-title 123
###xml 24 29 <span type="species:ncbi:9606">human</span>
Positive selection on a human-specific transcription factor binding site regulating IL4 expression.
###end article-title 123
###begin article-title 124
The interleukin-6 G(-174)C promoter polymorphism in the LURIC cohort: no association with plasma interleukin-6, coronary artery disease, and myocardial infarction.
###end article-title 124
###begin article-title 125
Interleukin-10 promoter polymorphism is associated with decreased breast cancer risk.
###end article-title 125
###begin article-title 126
###xml 72 80 <span type="species:ncbi:9606">patients</span>
Polymorphisms within the tumor necrosis factor-alpha promoter region in patients with HLA-B27 associated uveitis: association with susceptibility and clinical manifestations.
###end article-title 126
###begin article-title 127
Role of the CCL2/MCP-1 -2518A>G gene polymorphism in HLA-B27 associated uveitis.
###end article-title 127
###begin article-title 128
Interleukin-8 promoter polymorphism -251A/T is a risk factor for age-related macular degeneration.
###end article-title 128
###begin article-title 129
Association of RANTES G-403A gene polymorphism with increased risk of coronary atherosclerosis.
###end article-title 129
###begin article-title 130
Inflammatory gene polymorphisms and ischemic heart disease: review of population association studies.
###end article-title 130
###begin article-title 131
###xml 146 154 <span type="species:ncbi:9606">patients</span>
A polymorphism in the promoter region of the tumor necrosis factor-alpha gene (-308) is associated with coronary heart disease in type 2 diabetic patients.
###end article-title 131
###begin article-title 132
The -308 G/A tumor necrosis factor-alpha gene dimorphism: a risk factor for unstable angina.
###end article-title 132
###begin article-title 133
Inflammation and atherosclerosis: the role of TNF and TNF receptors polymorphisms in coronary artery disease.
###end article-title 133
###begin article-title 134
###xml 51 54 <span type="species:ncbi:9606">men</span>
The RANTES -403G>A promoter polymorphism in Korean men: association with serum RANTES concentrations and coronary artery disease.
###end article-title 134
###begin article-title 135
Carotid intima-media thickness is associated with allelic variants of stromeolysin-1, interleukin-6, and hepatic lipase genes: the Northern Manhattan Prospective Cohort Study.
###end article-title 135
###begin article-title 136
Why most published research findings are false.
###end article-title 136

